Press Release – New York, NY – October 23, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, in a $2.05 million registered direct offering and concurrent private placement. The gross proceeds, before deducting the placement agent fees and other offering expenses payable by the Company, were approximately $2.05 million.
The SRFC team was led by partner Jay Yamamoto and associate Rohini Sud.
新闻稿 – 纽约州纽约 – 2024 年 10 月 23 日 – Sichenzia Ross Ference Carmel LLP 今天宣布，它代表 Calidi Biotherapeutics, Inc.（纽约证券交易所美国股票代码：CLDI），一家开发新一代靶向免疫疗法的临床阶段生物技术公司， 205万美元的注册直接发行和同步私募。扣除配售代理费用和公司应付的其他发行费用之前，总收益约为 205 万美元。
SRFC 团队由合伙人 Jay Yamamoto 和律师 Rohini Sud 领导。
